annual CFF:
-$211.79M+$782.00K(+0.37%)Summary
- As of today (June 22, 2025), AMRX annual cash flow from financing activities is -$211.79 million, with the most recent change of +$782.00 thousand (+0.37%) on December 31, 2024.
- During the last 3 years, AMRX annual CFF has fallen by -$73.67 million (-53.34%).
- AMRX annual CFF is now -173.62% below its all-time high of $287.68 million, reached on December 31, 2018.
Performance
AMRX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$39.17M+$22.04M(+36.01%)Summary
- As of today (June 22, 2025), AMRX quarterly cash flow from financing activities is -$39.17 million, with the most recent change of +$22.04 million (+36.01%) on March 31, 2025.
- Over the past year, AMRX quarterly CFF has dropped by -$16.01 million (-69.15%).
- AMRX quarterly CFF is now -108.37% below its all-time high of $467.98 million, reached on March 31, 2020.
Performance
AMRX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$227.80M-$16.01M(-7.56%)Summary
- As of today (June 22, 2025), AMRX TTM cash flow from financing activities is -$227.80 million, with the most recent change of -$16.01 million (-7.56%) on March 31, 2025.
- Over the past year, AMRX TTM CFF has dropped by -$4.97 million (-2.23%).
- AMRX TTM CFF is now -144.97% below its all-time high of $506.60 million, reached on September 30, 2018.
Performance
AMRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AMRX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.4% | -69.2% | -2.2% |
| 3 y3 years | -53.3% | +36.4% | -31.3% |
| 5 y5 years | -362.1% | -108.4% | -151.3% |
AMRX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -98.6% | +0.4% | -268.5% | +61.2% | -293.1% | +9.4% |
| 5 y | 5-year | -260.7% | +0.4% | -108.4% | +87.4% | -151.3% | +37.1% |
| alltime | all time | -173.6% | +0.4% | -108.4% | +87.4% | -145.0% | +37.1% |
AMRX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$39.17M(-36.0%) | -$227.80M(+7.6%) |
| Dec 2024 | -$211.79M(-0.4%) | -$61.20M(-33.7%) | -$211.79M(-15.8%) |
| Sep 2024 | - | -$92.35M(+163.2%) | -$251.42M(+2.3%) |
| Jun 2024 | - | -$35.09M(+51.5%) | -$245.66M(+10.2%) |
| Mar 2024 | - | -$23.16M(-77.0%) | -$222.83M(+4.8%) |
| Dec 2023 | -$212.57M(+99.4%) | -$100.83M(+16.5%) | -$212.57M(+58.7%) |
| Sep 2023 | - | -$86.58M(+606.5%) | -$133.91M(+43.3%) |
| Jun 2023 | - | -$12.26M(-5.0%) | -$93.45M(+61.3%) |
| Mar 2023 | - | -$12.90M(-41.8%) | -$57.95M(-45.6%) |
| Dec 2022 | -$106.62M(-22.8%) | -$22.17M(-51.9%) | -$106.62M(-7.1%) |
| Sep 2022 | - | -$46.13M(-298.4%) | -$114.80M(+2.3%) |
| Jun 2022 | - | $23.25M(-137.8%) | -$112.23M(-35.3%) |
| Mar 2022 | - | -$61.57M(+102.9%) | -$173.54M(+25.6%) |
| Dec 2021 | -$138.12M | -$30.35M(-30.3%) | -$138.12M(+16.0%) |
| Sep 2021 | - | -$43.55M(+14.4%) | -$119.05M(+31.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$38.07M(+45.6%) | -$90.31M(-75.1%) |
| Mar 2021 | - | -$26.15M(+131.8%) | -$362.32M(-374.9%) |
| Dec 2020 | $131.81M(-387.6%) | -$11.28M(-23.8%) | $131.81M(-2.9%) |
| Sep 2020 | - | -$14.81M(-95.2%) | $135.79M(-5.0%) |
| Jun 2020 | - | -$310.08M(-166.3%) | $143.00M(-67.8%) |
| Mar 2020 | - | $467.98M(-6512.4%) | $444.01M(-1068.8%) |
| Dec 2019 | -$45.83M(-115.9%) | -$7.30M(-3.9%) | -$45.83M(-82.2%) |
| Sep 2019 | - | -$7.60M(-16.3%) | -$257.45M(+53.9%) |
| Jun 2019 | - | -$9.07M(-58.5%) | -$167.26M(-155.9%) |
| Mar 2019 | - | -$21.86M(-90.0%) | $299.06M(+4.0%) |
| Dec 2018 | $287.68M(-402.8%) | -$218.92M(-365.0%) | $287.68M(-43.2%) |
| Sep 2018 | - | $82.60M(-81.9%) | $506.60M(+19.5%) |
| Jun 2018 | - | $457.24M(-1475.3%) | $424.00M(-1375.3%) |
| Mar 2018 | - | -$33.25M | -$33.25M |
| Dec 2017 | -$95.02M(+387.4%) | - | - |
| Dec 2016 | -$19.50M | - | - |
FAQ
- What is Amneal Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals annual CFF year-on-year change?
- What is Amneal Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals quarterly CFF year-on-year change?
- What is Amneal Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals TTM CFF year-on-year change?
What is Amneal Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of AMRX is -$211.79M
What is the all time high annual CFF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high annual cash flow from financing activities is $287.68M
What is Amneal Pharmaceuticals annual CFF year-on-year change?
Over the past year, AMRX annual cash flow from financing activities has changed by +$782.00K (+0.37%)
What is Amneal Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of AMRX is -$39.17M
What is the all time high quarterly CFF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high quarterly cash flow from financing activities is $467.98M
What is Amneal Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, AMRX quarterly cash flow from financing activities has changed by -$16.01M (-69.15%)
What is Amneal Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of AMRX is -$227.80M
What is the all time high TTM CFF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high TTM cash flow from financing activities is $506.60M
What is Amneal Pharmaceuticals TTM CFF year-on-year change?
Over the past year, AMRX TTM cash flow from financing activities has changed by -$4.97M (-2.23%)